ASCO 2021 | Lifileucel in advanced melanoma

James Larkin, PhD, FRCP, The Royal Marsden NHS Foundation Trust, London, UK, outlines follow-up data from the open-label, multicenter Phase II C-144-01 (NCT02360579) of lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma. Lifileucel consists of activated lymphocytes derived from the patient’s tumor and patients receiving lifileucel have progressed on anti-PD-1 immunotherapy and targeted therapies such as BRAF inhibitors. Dr Larkin reports an overall response rate (ORR) of 36.4% as well as a correlation between longer ORR and patients who received less anti-PD-1 therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.